The US Food and Drug Administration (FDA) has granted accelerated approval to several targeted therapies for non-small cell lung cancer (NSCLC) and other cancers. Telisotuzumab vedotin-tllv, a c-Met-directed antibody and microtubule inhibitor conjugate, received accelerated approval for adults with locally advanced or metastatic non-squamous NSCLC exhibiting high c-Met protein overexpression. Additionally, the FDA approved Dato-DXd for previously treated, locally advanced or metastatic EGFR-positive NSCLC, based on pooled data from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials. Sunvozertinib was also granted accelerated approval for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations, whose disease progressed following platinum-based chemotherapy. In other oncology developments, research continues on treatments for multiple myeloma, metastatic renal cell carcinoma (RCC), and pancreatic ductal adenocarcinoma (PDAC). Notable studies include the phase 3 DeLLphi-304 trial of tarlatamab in small-cell lung cancer after platinum-based chemotherapy, and a post hoc analysis of the phase 3 JAVELIN Renal 101 trial highlighting KIM-1 as a prognostic biomarker in advanced RCC. Investigations into the use of perioperative nivolumab in NSCLC and the potential of TIGIT blockade combined with chemotherapy and anti–PD-1 therapy in upper gastrointestinal cancers are ongoing. Promising efficacy has also been observed with certepetide plus gemcitabine/nab-paclitaxel in treatment-naive metastatic PDAC patients. Expert interviews discuss challenges and recommendations in managing multiple myeloma and metastatic RCC, as well as the implications of emerging therapies and potential FDA approvals.